Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)Tip Ranks·Aug 13 at 06:18 AMPLRX+3.13%
Pliant Therapeutics catat rugi bersih Q2 FY26 menyempit ke $ 22,37 juta; biaya R&D turun 48,05% ke $ 16,73 jutaPUBT·Aug 11 at 03:09 PMPLRX+3.13%
Pliant Therapeutics updates corporate status and posts Q2 2026 financials.Unusual Whales·Aug 11 at 03:08 PMPLRX+3.13%
Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLCMarket Beat·Jul 29 at 02:13 AMPLRX+3.13%JPM+0.01%
Coastal Financial (CCB) Could Be 52% Undervalued On Pliant US PartnershipSimplywall·Jul 14 at 12:08 PMCCB+0.38%PLRX+3.13%
Pliant Therapeutics director Flavia Borellini files initial beneficial ownership statementPUBT·Jul 13 at 03:33 PMPLRX+3.13%
Pliant Therapeutics appoints Flavia Borellini, Robert Iannone to boardPUBT·Jul 13 at 08:16 AMPLRX+3.13%
